中信证券：维持阿里健康“增持”评级 有望深度受益药品零售线上化迁移趋势

Core Insights - The National Healthcare Security Administration is strengthening the scrutiny of the use of medical insurance funds in pharmacies, which is expected to significantly benefit Alibaba Health's (00241) core pharmaceutical e-commerce business as the trend of online drug retailing continues to grow [1] - The company's traceability code business is positioned to provide essential technical support during this transition [1] - Alibaba Health is steadily advancing the testing of its "Hydrogen Ion" medical Q&A platform, leveraging AI to enhance service experience and improve operational efficiency in pharmaceutical search and recommendation scenarios [1] - The recommendation to maintain an "Overweight" rating reflects confidence in the company's growth prospects [1]